Mitsubishi UFJ Asset Management
CRSP icon

Mitsubishi UFJ Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$283K Buy
5,194
+315
+6% +$16.6K ﹤0.01% 974
2026
Q1 		$232K Buy
4,879
+303
+7% +$16K ﹤0.01% 953
2025
Q4 		$246K Sell
4,576
-1,527
-25% -$91.5K ﹤0.01% 987
2025
Q3 		$396K Buy
6,103
+12
+0.2% +$689 ﹤0.01% 902
2025
Q2 		$296K Buy
6,091
+366
+6% +$14.2K ﹤0.01% 923
2025
Q1 		$195K Buy
5,725
+473
+9% +$20.1K ﹤0.01% 960
2024
Q4 		$215K Buy
5,252
+372
+8% +$17.6K ﹤0.01% 979
2024
Q3 		$229K Sell
4,880
-454
-9% -$23K ﹤0.01% 947
2024
Q2 		$288K Buy
5,334
+2,002
+60% +$116K ﹤0.01% 923
2024
Q1 		$227K Sell
3,332
-149
-4% -$10.7K ﹤0.01% 948
2023
Q4 		$218K Sell
3,481
-1,003
-22% -$55.4K ﹤0.01% 1000
2023
Q3 		$204K Buy
4,484
+76
+2% +$3.92K ﹤0.01% 1021
2023
Q2 		$247K Sell
4,408
-272
-6% -$15.4K ﹤0.01% 1016
2023
Q1 		$212K Buy
4,680
+327
+8% +$15.9K ﹤0.01% 1021
2022
Q4 		$178K Sell
4,353
-111
-2% -$5.89K ﹤0.01% 1035
2022
Q3 		$292K Buy
4,464
+88
+2% +$6.38K ﹤0.01% 982
2022
Q2 		$266K Buy
4,376
+609
+16% +$35.8K ﹤0.01% 1012
2022
Q1 		$236K Buy
3,767
+300
+9% +$18.8K ﹤0.01% 1032
2021
Q4 		$275K Buy
3,467
+668
+24% +$58.4K ﹤0.01% 1028
2021
Q3 		$313K Hold
2,799
– – ﹤0.01% 1008
2021
Q2 		$453K Sell
2,799
-495
-15% -$60.2K ﹤0.01% 968
2021
Q1 		$401K Buy
3,294
+1,038
+46% +$157K ﹤0.01% 917
2020
Q4 		$345K Sell
2,256
-729
-24% -$86.2K ﹤0.01% 874
2020
Q3 		$250K Sell
2,985
-14
-0.5% -$1.24K ﹤0.01% 871
2020
Q2 		$220K Buy
2,999
+389
+15% +$22.7K ﹤0.01% 877
2020
Q1 		$111K Buy
2,610
+597
+30% +$30.8K ﹤0.01% 919
2019
Q4 		$120K Sell
2,013
-1,642
-45% -$89.7K ﹤0.01% 939
2019
Q3 		$150K Buy
3,655
+595
+19% +$28.4K ﹤0.01% 860
2019
Q2 		$144K Sell
3,060
-1,160
-27% -$46.4K ﹤0.01% 872
2019
Q1 		$151K Buy
4,220
+233
+6% +$8.06K ﹤0.01% 831
2018
Q4 		$112K Buy
3,987
+1,765
+79% +$61.4K ﹤0.01% 832
2018
Q3 		$99K Buy
+2,222
New +$116K ﹤0.01% 857

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mitsubishi UFJ Asset Management's CRSP Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management increased its CRISPR Therapeutics (CRSP) stake by 6.5% in Q2 2026, buying an estimated $16.6K and bringing the position to 5,194 shares worth $283K. The position accounts for ﹤0.01% of the portfolio, ranked #974.

Mitsubishi UFJ Asset Management first reported a position in CRSP in Q3 2018 and has held it in 32 quarters since. The position peaked at $453K in Q2 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Mitsubishi UFJ Asset Management held 5,194 shares of CRISPR Therapeutics worth $283K as of Q2 2026.
  • Mitsubishi UFJ Asset Management bought 315 CRISPR Therapeutics shares in Q2 2026, an estimated $16.6K.
  • CRISPR Therapeutics made up ﹤0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #974 holding.
  • Mitsubishi UFJ Asset Management first reported a position in CRISPR Therapeutics in Q3 2018 and has held it in 32 quarters since.
  • Mitsubishi UFJ Asset Management's CRISPR Therapeutics position peaked at $453K in Q2 2021.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.